# US 2013/0252932 A1 · Localized modulation of tissues and cells to enhance therapeutic effects including renal denervation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252932 A1
- Document ID: US20130252932A1
- Status: Published application
- Kind: A1
- Application number: 13/656,413
- Filed: 2012-10-19
- Published: 2013-09-26
- Earliest claimed: 2011-10-19
- Assignees: Mercator MedSystems, Inc.
- Applicants: Mercator Medsystems, Inc.
- Inventors: Kirk P. SEWARD
- Web page: https://patentgrep.com/patent/US20130252932A1

## CPC

- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 295/13: to an acyclic saturated chain
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Pharmaceutical preparations, compositions, systems, and devices including medical devices and diagnostic or therapeutic agents, and methods to treat disease by modification of local tissue environment to modulate the therapeutic index of locally or systemically delivered therapeutic or diagnostic agents. Improved ability to reduce sympathetic nerve activity in the adventitia and perivascular tissues around arteries and veins in the body. Modulation of the local tissue environment around an artery to enable more effective denervation with or without a therapeutic agent. Modulation may include adjustment of the pH of the tissue.

## Claims

### Claim 1

A composition comprising a guanidine with pH>8.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the guanidine is guanethidine.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the guanethidine includes monosulfate, hemisulfate in a solution configured for denervation, or hemisulfate in a solution suitable for denervation.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The composition of claim 1, wherein the pH>9, or the pH>10.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The composition of claim 1, further comprising an alkaline buffer.

### Claim 9 (depends on 8)

The composition of claim 8, wherein the alkaline buffer comprises NaOH, NaOH in a molar ratio to the guanidine concentration of 50% or greater, or NaOH in an equimolar or greater concentration to the guanidine.

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 1)

The composition of claim 1, wherein the composition further comprises sodium chloride that is 0.7% to 0.9% of the solution.

### Claim 14

(canceled)

### Claim 15 (depends on 3)

The composition of claim 3, wherein the guanethidine monosulfate is in concentration of 0.1 mg/mL to 50 mg/mL, or in concentration of 1 mg/mL to 20 mg/mL.

### Claim 16

(canceled)

### Claim 17

A method for modulating local tissue physiology comprising the delivery of preparation comprising a liquid, gel, or semisolid into the tissue, wherein the preparation buffers the local tissue physiology by raising or lowering the pH of the local tissue.

### Claim 18

(canceled)

### Claim 19 (depends on 17)

The method of claim 17, wherein the preparation comprises a therapeutic agent that has its index effect at a physiological condition modulated by the delivery of such preparation, but not having an index effect at neutral physiological condition.

### Claim 20 (depends on 17)

The method of claim 17, wherein the preparation further includes a therapeutic agent that has additional or enhanced index effect at a physiological condition modulated by the delivery of such preparation, but not having such additional or enhanced index effect at neutral physiological condition.

### Claim 21 (depends on 17)

The method of claim 17, wherein the gel comprises a hydrogel that consumes protons as it resorbs in the tissue.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24 (depends on 17)

The method of claim 17, wherein the preparation includes guanethidine monosulfate, or has a pH>8, or includes guanethidine monosulfate and has a pH>8.

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

A method of creating renal denervation comprising the localized delivery of an acid or base with sufficiently low or high pH to create localized nerve damage or destruction.

### Claim 28

A method of creating renal denervation comprising the localized delivery of a non-isotonic or non-isoosmolar solution that creates neuronal destruction while sparing other local tissues.

### Claim 29

A method comprising the delivery of a preparation of guanethidine monosulfate at pH>8 or guanethidine hemisulfate at pH>8 into the renal artery adventitia and perivascular tissues which is effective in treating hypertension, in treating heart failure, in treating insulin resistance, in treating systemic inflammation, or in treating sleep apnea.

### Claim 30

(canceled)

### Claim 31

(canceled)

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38

A method of creating renal denervation comprising the localized delivery of a first toxin entering cells through sodium channels, wherein such first toxin comprises one or more of: tetrodotoxin and batrachotoxin, a second toxin entering cells through potassium channels, wherein such second toxin comprises one or more of: maurotoxin, agitoxin, charybdotoxin, margatoxin, slotoxin, sycllatoxin and hefutoxin, and/or a third toxin entering cells through calcium channels, wherein such third toxin comprises one or more of: calciseptine, taicatoxin, calcicludine and PhTx3.

### Claim 39

A method of creating renal denervation comprising the localized delivery of an agent,
wherein the agent itself or a composition comprising such agent has a pH of at least 7, a pH of at most 11, a pH of at least 7 and at most 11, a pH of at least 8 and at most 10, a pH that is effective to denervate nerves to which such agent is delivered, or a pH that is adjusted to a level that is effective to denervate nerves to which such agent is delivered;
wherein the agent itself or a composition comprising such agent has a pH of at most 7, a pH of at least 3, a pH of at most 7 and at least 3, a pH of at most 6 and at least 4, an acidic pH that is effective to denervate nerves to which such agent is delivered, or an acidic pH that is adjusted to a level that is effective to denervate nerves to which such agent is delivered;
wherein tissue into which the agent is delivered is modulated to a pH of at least 7, a pH of at most 11, a pH of at least 7 and at most 11, a pH of at least 8 and at most 10, or to a pH that is effective to denervate nerves to which such agent is delivered; or
wherein tissue into which the agent is delivered is modulated to a pH of at most 7, a pH of at least 3, a pH of at most 7 and at least 3, a pH of at most 6 and at least 4, an acidic pH that is effective to denervate nerves to which such agent is delivered.

### Claim 40 (depends on 39)

The method of claim 39, wherein the agent comprises an adrenergic blocker, an androgenic inhibitor, an adrenergic stimulator, an Alpha-/beta-adrenergic blocker, an angiotensin converting enzyme (ACE) inhibitor, an ACE-receptor antagonist, a Beta blocker, a calcium channel blocker, an antiarrythmic of groups I-IV, an antiarrythmic, a cardiotonic, an alpha-2-agonists, a guanidine derivative, an imadazoline receptor agonist, a ganglion-blocking agent, nicotinic antagonist, ganglion-blocking agents, nicotinic antagonist, a MAOI inhibitor, an adrenergic uptake inhibitor, a tyrosine hydroxylase inhibitors, an alpha-1 blocker, a non-selective alpha blocker, a serotonin antagonist, an endothelin antagonist, a sclerosing agent, a sensory denervation agent, doxazosin, guanadrel, guanethidine, pheoxybenzamine, prazosin plus polythiazide, terazosin, methyldopa, clonidine, guanabenz, guanfacine, Labetalol, benazepril, catopril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, quinapril, ramipril, and combinations with calcium channel blockers and diuretics, losartan, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, esmolol, fimolol, pindolol, propranolol, penbatolol, metoprolol, nadolol, sotalol, Amiloride, amlodipine, bepridil, diltiazem, isradipine, nifedipine, verapamil, felodipine, nicardipine, nimodipine, bretylium, disopyramide, encamide, flecamide, lidocaine, mexiletine, moricizine, propafenone, procainamide, quinidine, tocamide, esmolol, propranolol, acebutolol, amiodarone, sotalol, verapamil, diltiazem, pindolol, bupranolol hydrochloride, trichlormethiazide, furosemide, prazosin hydrochloride, metoprolol tartrate, carteolol hydrochloride, oxprenolol hydrochloride, and propranolol hydrochloride, adenosine, digoxin; metildigoxin, caffeine, dopamine hydrochloride, dobutamine hydrochloride, octopamine hydrochloride, diprophylline, ubidecarenon, digitalis, capsaicin, anti-nerve growth factor, anti-dopamine beta-hydroxylase, anti-acetylcholinesterase, 6-hydroxyldopamine (6-OHDA), bretylium tosylate, guanacline, and N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4), OX7-SAP, 192-SAP, anti-dopamine beta-hydroxylase saporin (DBH-SAP), and anti-dopamine beta-hydroxylase immunotoxin (DHIT), phenol, ethanol, clonidine, guanfacine, methyldopa, betanidine, guanoxan, debrisoquine, guanoclor, guanazodine, guanoxabenz, moxonidine, relmenidine, mecamylamine, trimethaphan, pargyline, rescinnamine, reserpine, metirosine, prazosin, indoramin, trimazosin, doxazosin, urapidil, phentolamine, ketanserin, bosentan, ambrisentan, sitaxentan, quinacrine, chloroquine, sodium tetradecyl sulfate, ethanolamine oleate, sodium morrhuate, polidocanol, or a hypertonic solution.

### Claim 41

(canceled)

### Claim 42

(canceled)

### Claim 43 (depends on 39)

The method of claim 39, wherein the tissue is modulated before, after or during the delivery of the agent to the tissue.

### Claim 44

(canceled)

### Claim 45

(canceled)

### Claim 46

(canceled)

### Claim 47

A method for enhancing the uptake of therapeutic agents into tissue comprising
modulating pH of the tissue by creating a zone of the tissue having a center and an outer edge, and delivering a therapeutic agent into the zone,
wherein the zone comprises a modulated pH as compared to a pre-modulation pH of the tissue prior to modulation or as compared to a neutral pH,
wherein zone comprises a gradient of pH that is most modulated at the center of the zone and reduces to the pre-modulation pH of the tissue or to neutral pH at the outer edge of the zone, and
wherein enhanced uptake of a therapeutic agent occurs in the zone as compared to uptake that would occur into tissue at the pre-modulation pH or at neutral pH.

### Claim 48

(canceled)

### Claim 49 (depends on 47)

The method of claim 47, wherein the therapeutic agent is delivered systemically and the modulating of the tissue pH enhances a buildup of the therapeutic agent in the zone or improves a therapeutic index in the zone.

### Claim 50

(canceled)

### Claim 51

(canceled)

### Claim 52

(canceled)

### Claim 53

(canceled)

### Claim 54

(canceled)

### Claim 55 (depends on 47)

The method of claim 47, wherein the therapeutic agent comprises guanethidine monosulfate or guanethidine hemisulfate.

### Claim 56

(canceled)

### Claim 57 (depends on 47)

The method of claim 47, wherein the modulated pH at least 7, at most 11, at least 7 and at most 11, at least 8 and at most 10, or a predetermined pH that is effective to denervate nerves to which such therapeutic agent is delivered.

### Claim 58 (depends on 39)

The method of claim 39, wherein the agent is chosen from the following: guanethidine in a concentration ranging from 1 μg/mL to 50 mg/mL at pH of greater than 7, guanethidine in a concentration ranging from 1 mg/mL to 30 mg/mL at pH of greater than 7, a composition comprising guanethidine having a sodium chloride content between 0.7% and 0.9%, a composition comprising guanethidine having pH of about 9.5, a composition comprising guanethidine having pH that is adjusted to about 9.5 by buffering with an alkaline buffer agent, a composition comprising guanethidine having pH that is adjusted to about 9.5 by buffering with sodium hydroxide, or a composition comprising guanethidine having pH of between 8 and 11.
